Page 267 - Glucose Monitoring Devices

274 CHAPTER 13 Low glucose suspend systems

[52] Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M,
Hanaire H. Cost-effectiveness of sensor-augmented pump therapy with low glucose
suspend versus standard insulin pump therapy in two different patient populations
with type 1 diabetes in France. Diabetes Technology and Therapeutics February
2016;18(2):75e84.
[53] National Institute for Health and Care Excellence (NICE) evidence overview. Type 1 dia-
betes: integrated sensor-augmented pump therapy systems for managing blood glucose
levels. Available from: https://www.nice.org.uk/guidance/dg21/documents/type-1-
diabetes-managing-blood-glucose-levels-the-minimed-paradigm-veo-system-and-the-vib
e-and-g4-platinum-cgm-system-committee-papers2. [Accessed 18 December 2018].
[54] Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circulation:
Cardiovascular Quality and Outcomes January 2009;2(1):55e8.
[55] Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of
diabetes: past, present, and future. Diabetes Technology and Therapeutics August
2014;16(8):477e90.
[56] Zhong A, Choudhary P, McMahon C, Agrawal P, Welsh JB, Cordero TL, Kaufman FR.
Effectiveness of automated insulin management features of the MiniMedÒ 640G
sensor-augmented insulin pump. Diabetes Technology and Therapeutics October
2016;18(10):657e63.
[57] De Valk HW, Lablanche S, Bosi E, Choudhary P, Silva JD, Castaneda J, Vorrink L, De
Portu S, Cohen O. Study of MiniMed 640G insulin pump with SmartGuard in preven-
tion of low glucose events in adults with type 1 diabetes (SMILE): design of a hypogly-
cemia prevention trial with continuous glucose monitoring data as outcomes. Diabetes
Technology and Therapeutics November 2018;20(11):758e66.
[58] Beato-Vı ´bora PI, Gil-Poch E, Gala ´n-Bueno L, La ´zaro-Martı ´n L, Arroyo-Dı ´ez FJ. The
incremental benefits of the predictive low-glucose suspend function compared to the
low-glucose suspend function as automation against hypoglycemia in sensor-
augmented pump therapy. Journal of Diabetes Science and Technology November
2018;12(6):1241e3.
[59] Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L,
Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW,
Kollman C, Woodall W, Beck RW. Predictive low-glucose suspend reduces hypoglyce-
mia in adults, adolescents, and children with type 1 diabetes in an at-home randomized
crossover study: results of the PROLOG trial. Diabetes Care October 2018;41(10):
2155e61.
[60] Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV,
Kaufman FR. Safety of a hybrid closed-loop insulin delivery system in patients with
type 1 diabetes. Journal of the American Academy of Dermatology October 4, 2016;
316(13):1407e8.
[61] Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS,
Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A,
Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose outcomes with the in-home use
of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1
diabetes. Diabetes Technology and Therapeutics March 2017;19(3):155e63.